AbbVie Inc. experienced a significant stock decline of over 8% after announcing its first-quarter earnings, which included a revenue of $13.54 billion, falling short of expectations. Despite reporting earnings per share of $3.16, the company lowered its annual adjusted EPS guidance and missed key top-line estimates, raising concerns about growing competition for its blockbuster drug Humira. Analysts suggest there may be a buying opportunity in the dip, yet uncertainty about AbbVie's reliance on Humira amid upcoming patent expirations looms.
“Humira · is AbbVie Inc.'s · blockbuster drug against rheumatoid arthritis”
“AbbVie · stock has tumbled · over 8% · true”
“AbbVie · reported revenue of · $13.54 billion · true”
“AbbVie · quarterly earnings · $3.16 per share · beating the Zacks Consensus Estimate of $3.15 per share”
“AbbVie (ABBV) · has · forward yield · 3.64%”
“AbbVie · pays · dividend yield · 3.64%”
“AbbVie · market cap · value · $277 billion”
“AbbVie · dividend yield · value · 3.64%”
“AbbVie · sales growth · last year · 22.7%”
“AbbVie · forecasted earnings per share growth · value · 11%”
“AbbVie · dividends paid out · last year · $9.26 billion”
“AbbVie Inc. · is an American biopharmaceutical company · develops and distributes commercial drugs for various diseases · true”
